Immvira Reports 100% Complete Response Rate At 9 Months In Bladder Carcinoma In Situ With MVR-T3011 At ASCO

(MENAFN - PR Newswire) SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy ...